Lotze MT - Search Results

1

Changes in laboratory results for cancer patients treated with interleukin-2.

Huang CM, Elin RJ, Ruddel M, Sliva C, Lotze MT, Rosenberg SA. Huang CM, et al. Among authors: lotze mt. Clin Chem. 1990 Mar;36(3):431-4. Clin Chem. 1990. PMID: 2311209

2

Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients.

Kragel AH, Travis WD, Feinberg L, Pittaluga S, Striker LM, Roberts WC, Lotze MT, Yang JJ, Rosenberg SA. Kragel AH, et al. Among authors: lotze mt. Hum Pathol. 1990 May;21(5):493-502. doi: 10.1016/0046-8177(90)90005-p. Hum Pathol. 1990. PMID: 2338330

3

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

Fisher B, Keenan AM, Garra BS, Steinberg SM, White DE, DiBisceglie AM, Hoofnagle JH, Yolles P, Rosenberg SA, Lotze MT. Fisher B, et al. Among authors: lotze mt. J Clin Oncol. 1989 Dec;7(12):1852-62. doi: 10.1200/JCO.1989.7.12.1852. J Clin Oncol. 1989. PMID: 2585024

4

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE. Rosenberg SA, et al. Among authors: lotze mt. J Clin Oncol. 1989 Dec;7(12):1863-74. doi: 10.1200/JCO.1989.7.12.1863. J Clin Oncol. 1989. PMID: 2685181 Clinical Trial.

5

Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens.

Wiebke EA, Rosenberg SA, Lotze MT. Wiebke EA, et al. Among authors: lotze mt. J Clin Oncol. 1988 Sep;6(9):1440-9. doi: 10.1200/JCO.1988.6.9.1440. J Clin Oncol. 1988. PMID: 3262151

6

Interleukin 2 and psoriasis.

Lee RE, Gaspari AA, Lotze MT, Chang AE, Rosenberg SA. Lee RE, et al. Among authors: lotze mt. Arch Dermatol. 1988 Dec;124(12):1811-5. Arch Dermatol. 1988. PMID: 3263840

7

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

Rosenberg SA, Lotze MT, Mulé JJ. Rosenberg SA, et al. Among authors: lotze mt. Ann Intern Med. 1988 Jun;108(6):853-64. doi: 10.7326/0003-4819-108-6-853. Ann Intern Med. 1988. PMID: 3285747 Review.

8

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

Ognibene FP, Rosenberg SA, Lotze M, Skibber J, Parker MM, Shelhamer JH, Parrillo JE. Ognibene FP, et al. Chest. 1988 Oct;94(4):750-4. doi: 10.1378/chest.94.4.750. Chest. 1988. PMID: 3262487

9

A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy.

Lange JR, Raubitschek AA, Pockaj BA, Spencer WF, Lotze MT, Topalian SL, Yang JC, Rosenberg SA. Lange JR, et al. Among authors: lotze mt. J Immunother (1991). 1992 Nov;12(4):265-71. doi: 10.1097/00002371-199211000-00007. J Immunother (1991). 1992. PMID: 1477077 Clinical Trial.

10

Delayed reactions to contrast media after interleukin-2 immunotherapy.

Choyke PL, Miller DL, Lotze MT, Whiteis JM, Ebbitt B, Rosenberg SA. Choyke PL, et al. Among authors: lotze mt. Radiology. 1992 Apr;183(1):111-4. doi: 10.1148/radiology.183.1.1549655. Radiology. 1992. PMID: 1549655

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

573 results

Search Page

Filters